Investor Conference Call on Xarelto COMPASS Data at ESC Congress 2017

Monday, August 28, 2017
Start approx. 1:30 p.m. CEST (11:30 a.m. UTC)

Full data from the Phase III COMPASS Study with Xarelto (Rivaroxaban) have been featured in Hot Line presentations at ESC Congress 2017 on August 27, 2017 in Barcelona, Spain. On this occasion we hosted a conference call for investors and analysts on August 28, 2017.

Investor News on Xarelto COMPASS Data


Dr. Jörg Möller
Head of Global Development at Pharmaceuticals

Dr. Frank Misselwitz
Head of the Therapeutic Area Thrombosis and Hematology

You can also play the audio recording on your mobile device.

with
Dr. Jörg Möller, Head of Global Development at Pharmaceuticals
Dr. Frank Misselwitz, Head of the Therapeutic Area Thrombosis and Hematology
Oliver Maier, Head of Bayer Investor Relations

On-demand audio recording of the investor conference call (including slides)

Audio recording of the investor conference call
(MP3 format)

You can also play the audio recording on your mobile device.

Presentation Charts
Download (PDF, 947 KB) collect
Transcript

Download (PDF, 64 KB) collect

Investor News on Xarelto COMPASS Data